Effect of Sulodexide in Overt Diabetic Nephropathy

PHASE4TerminatedINTERVENTIONAL
Enrollment

968

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Diabetic Nephropathy
Interventions
DRUG

Sulodexide

100 mg gelcap in the morning and evening

DRUG

Placebo

1 placebo gelcap in the morning and evening

Trial Locations (3)

3168

The Collaborative Study Group, Clinical Coordinating Center for the Pacific Region, Monash Medical Center, Melbourne

60612

The Collaborative Study Group, Clinical Coordinating Center for U.S. and Canadian clinics, Rush University Medical Center, Chicago

9713 AV

The Collaborative Study Group, Clinical Coordinating Center for European Clinics, University of Groningen, Groningen

Sponsors
All Listed Sponsors
collaborator

Collaborative Study Group (CSG)

NETWORK

lead

Keryx Biopharmaceuticals

INDUSTRY